Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer ; day:23 ; month:4 ; year:2016 ; pages:1-12
Breast cancer research and treatment ; (23.4.2016), 1-12
- Creator
-
Gallagher, Christopher M.
- Contributor
-
More, Kenneth
Kamath, Tripthi
Masaquel, Anthony
Guerin, Annie
Ionescu-Ittu, Raluca
Gauthier-Loiselle, Marjolaine
Nitulescu, Roy
Sicignano, Nicholas
Butts, Elizabeth
Wu, Eric Q.
Barnett, Brian
SpringerLink (Online service)
- DOI
-
10.1007/s10549-016-3790-3
- URN
-
urn:nbn:de:1111-2016042432050
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gallagher, Christopher M.
- More, Kenneth
- Kamath, Tripthi
- Masaquel, Anthony
- Guerin, Annie
- Ionescu-Ittu, Raluca
- Gauthier-Loiselle, Marjolaine
- Nitulescu, Roy
- Sicignano, Nicholas
- Butts, Elizabeth
- Wu, Eric Q.
- Barnett, Brian
- SpringerLink (Online service)
Other Objects (12)
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Survival after heart transplantation for non-metastatic primary cardiac sarcoma
Smoking cessation and survival among people diagnosed with non-metastatic cancer
Metabolic abnormalities and survival among patients with non-metastatic breast cancer
Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer
Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Survival after heart transplantation for non-metastatic primary cardiac sarcoma
Smoking cessation and survival among people diagnosed with non-metastatic cancer
Metabolic abnormalities and survival among patients with non-metastatic breast cancer
Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer
Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Survival after heart transplantation for non-metastatic primary cardiac sarcoma
Smoking cessation and survival among people diagnosed with non-metastatic cancer
Metabolic abnormalities and survival among patients with non-metastatic breast cancer
Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer